A Phase I Study of Intralesional Administration of an Adenovirus Vector Expressing the HSV-1 Thymidine Kinase Gene (AdV.RSV-TK) in Combination with Escalating Doses of Ganciclovir in Patients with Cutaneous Metastatic Malignant Melanoma
- 10 February 2000
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 11 (3) , 487-503
- https://doi.org/10.1089/10430340050015950
Abstract
The only peer-reviewed journal focused on the rapidly moving field of 3D printing and related technologies, providing comprehensive coverage of academic research and industrial and commercial developments that have applications in medicine, education, food, and architecture.This publication has 43 references indexed in Scilit:
- Cancer statistics, 1998CA: A Cancer Journal for Clinicians, 1998
- In situ delivery of suicide genes for cancer treatmentEuropean Journal Of Cancer, 1994
- Adenovirus‐mediated gene therapy of experimental gliomasJournal of Neuroscience Research, 1994
- Retroviral Transfer of Herpes Simplex Thymidine Kinase Gene into Glioma Cells Causes Targeting of Gancyclovir Cytotoxic EffectNeurologia medico-chirurgica, 1994
- In VitroEvidence That Metabolic Cooperation Is Responsible for the Bystander Effect Observed with HSVtkRetroviral Gene TherapyHuman Gene Therapy, 1993
- Gene therapy of maliganant brain tumors: A rat glioma line bearing the herpes simplex virus type 1‐thymidine kinase gene and wild type retrovirus kills other tumor cellsJournal of Neuroscience Research, 1992
- GanciclovirDrugs, 1990
- Model Predicting Survival in Stage I Melanoma Based on Tumor ProgressionJNCI Journal of the National Cancer Institute, 1989
- The emerging epidemic of melanoma and squamous cell skin cancerJAMA, 1989
- The rate of malignant melanoma in the United States: Are we making an impact?Journal of the American Academy of Dermatology, 1987